The rate of venous thromboembolism is higher than previously reported in retrospective studies.
New cancer therapies and statins demonstrate efficacy in treating and perhaps even preventing ovarian cancer recurrence.
Tumor emboli can occur in patients with cancer and carry with them a risk for serious complications.
Major challenges exist for hospitals with respect to publicly reported cancer metrics, according to research presented at SSO 2013.
Oncologists should be aware of possible complications associated with administering anticoagulants to patients with cancer.
Vascular endothelial growth factor receptor tyrosine-kinase inhibitors do not appear to be associated with an increased risk of venous thrombotic events in patients with advanced cancers.
Global experts called on colleagues attending the 54th American Society of Hematology Annual Meeting and Exposition to help disseminate and implement the first International Good Clinical Practice Guidelines for the use of antithrombotics.
Patients with advanced solid tumors treated with cisplatin have a significant increased risk of venous thromboembolism compared with non-cisplatin-based chemotherapy.
Erythropoietin stimulating agents and granulocyte colony stimulating factor do not affect OS among patients with ovarian cancer who receive bevacizumab plus chemotherapy, but ESA is associated with a significantly-elevated risk of venous thrombotic events.